Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-masked, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of Two Regimens of Intravitreal BI 771716 Against Pegcetacoplan in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration VERDANT Trial

NCT06722157 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06722157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06722157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-masked, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of Two Regimens of Intravitreal BI 771716 Against Pegcetacoplan in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration VERDANT Trial
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 6, 2025
Completion date
October 28, 2026
Enrollment
202 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy, macular degeneration, age-related